10x Genomics (TXG) Earnings Analysis
10x Genomics (TXG) next reports earnings on 2026-08-06, consensus EPS -0.23 USD. Last quarter (2026-05-07) it beat with EPS -0.1 USD vs -0.29 USD est (+65.5%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E -276.76.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does TXG next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.23 USD |
| Revenue estimate | 0.15B |
TXG earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.1 USD | -0.29 USD | +65.5% | Beat |
| 2026-02-12 | -0.13 USD | -0.19 USD | +31.6% | Beat |
| 2025-11-06 | -0.22 USD | -0.07 USD | -214.3% | Miss |
| 2025-08-07 | 0.28 USD | -0.35 USD | +180% | Beat |
| 2025-02-12 | -0.4 USD | -0.29 USD | -37.9% | Miss |
| 2024-08-08 | -0.32 USD | -0.47 USD | +31.9% | Beat |
Beat rate: 4/6 (67%) over reported quarters with consensus data.
TXG valuation and analyst view
| Trailing P/E | -276.76 |
|---|---|
| Trailing EPS | -0.1766 USD |
| Price / book | 7.41 |
| Dividend yield | 0.00% |
| Market cap | 6.07B |
| Analyst consensus | Hold (10 buy / 11 hold / 1 sell) |
| Avg price target | 37.8 USD |
Related research pages
Frequently asked questions
When is 10x Genomics (TXG)'s next earnings date?
10x Genomics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.23 USD and revenue estimate of 0.15B.
Did TXG beat earnings last quarter?
In its 2026-05-07 report, TXG posted EPS of -0.1 USD versus a -0.29 USD estimate — a beat of 65.5%.
What is TXG's earnings track record?
Over the last 6 reported quarters with consensus data, TXG beat estimates 4 times (67%).
What is TXG's current P/E ratio and EPS?
TXG trades at a trailing P/E of -276.76 on trailing EPS of -0.1765983037037636 USD.
What do analysts rate TXG?
Analyst consensus is "Hold" across 22 ratings (0 strong buy, 10 buy, 11 hold, 1 sell, 0 strong sell). Average 12-month price target: 37.8 USD.